【Midatech Pharma – MTX110】Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma

Partner News

1st June 2022- Midatech Pharma issued a press release, which is summarized as follows

Midatech Pharma is pleased to announce that its development programme of MTX110 for the treatment of recurrent glioblastoma (“rGBM”) has been granted Fast Track designation by the U.S. Food and Drug Administration (“FDA”).

Fast Track is a process designed to facilitate the development and expedite the review of treatments for serious conditions and that potentially address unmet medical needs. Drugs that are granted this designation are given the opportunity for more frequent interactions with the FDA, as well as potential pathways for expedited approval.

Original website link: https://www.midatechpharma.com/news/midatech-pharma-granted-fast-track